A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Daily CF101 Administered Orally for 12 Weeks to Patients With Osteoarthritis of the Knee
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2015
At a glance
- Drugs Piclidenoson (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- 21 Dec 2015 Last checked against ClinicalTrials.gov record.
- 16 Dec 2015 Planned End Date changed from 1 Dec 2016 to 1 Jan 2019 as reported by ClinicalTrials.gov.
- 16 Dec 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018 as reported by ClinicalTrials.gov.